| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 产品销售收入(元) | 637,299,366.93 | - | 483,168,069.99 | - | 614,022,476.05 |
| 技术权益及服务收入(元) | 20,371,496.30 | 110,525,540.38 | 36,362,001.79 | - | 29,766,533.40 |
| 技术收入(元) | - | - | - | 39,217,681.72 | - |
| 抗病毒类(元) | - | 69,703,365.39 | - | 174,411,201.50 | - |
| 抗真菌类(元) | - | 320,092,253.29 | - | 407,165,738.06 | - |
| 免疫抑制类(元) | - | 104,844,345.20 | - | 82,043,290.31 | - |
| 权益分成收入(元) | - | - | - | 60,036,773.87 | - |
| 制剂类(元) | - | 176,190,658.80 | - | 161,149,894.50 | - |
| 其他类产品(元) | - | 408,148,845.34 | - | 324,256,954.02 | - |
| 营业成本(元) | |||||
| 产品销售收入(元) | 269,773,505.24 | - | 259,712,577.07 | - | 283,869,053.93 |
| 技术权益及服务收入(元) | 1,770,466.53 | 15,159,629.07 | 1,605,582.02 | - | 453,995.19 |
| 技术收入(元) | - | - | - | 18,173,525.70 | - |
| 抗病毒类(元) | - | 61,808,742.48 | - | 116,638,603.64 | - |
| 抗真菌类(元) | - | 88,268,155.42 | - | 104,538,142.32 | - |
| 免疫抑制类(元) | - | 49,732,134.19 | - | 39,175,642.38 | - |
| 权益分成收入(元) | - | - | - | - | - |
| 制剂类(元) | - | 105,676,845.57 | - | 57,134,870.54 | - |
| 其他类产品(元) | - | 246,815,509.22 | - | 180,939,841.86 | - |
| 毛利(元) | |||||
| 产品销售收入(元) | 367,525,861.69 | - | 223,455,492.92 | - | 330,153,422.12 |
| 技术权益及服务收入(元) | 18,601,029.77 | 95,365,911.31 | 34,756,419.77 | - | 29,312,538.21 |
| 技术收入(元) | - | - | - | 21,044,156.02 | - |
| 抗病毒类(元) | - | 7,894,622.91 | - | 57,772,597.86 | - |
| 抗真菌类(元) | - | 231,824,097.87 | - | 302,627,595.74 | - |
| 免疫抑制类(元) | - | 55,112,211.01 | - | 42,867,647.93 | - |
| 权益分成收入(元) | - | - | - | 60,036,773.87 | - |
| 制剂类(元) | - | 70,513,813.23 | - | 104,015,023.96 | - |
| 其他类产品(元) | - | 161,333,336.12 | - | 143,317,112.16 | - |
| 毛利率(%) | |||||
| 产品销售收入(%) | 57.67 | - | 46.25 | - | 53.77 |
| 技术权益及服务收入(%) | 91.31 | 86.28 | 95.58 | - | 98.47 |
| 技术收入(%) | - | - | - | 53.66 | - |
| 抗病毒类(%) | - | 11.33 | - | 33.12 | - |
| 抗真菌类(%) | - | 72.42 | - | 74.33 | - |
| 免疫抑制类(%) | - | 52.57 | - | 52.25 | - |
| 权益分成收入(%) | - | - | - | - | - |
| 制剂类(%) | - | 40.02 | - | 64.55 | - |
| 其他类产品(%) | - | 39.53 | - | 44.20 | - |
| 收入构成(%) | |||||
| 产品销售收入(%) | 96.90 | - | 93.00 | - | 95.38 |
| 技术权益及服务收入(%) | 3.10 | 9.29 | 7.00 | - | 4.62 |
| 技术收入(%) | - | - | - | 3.14 | - |
| 抗病毒类(%) | - | 5.86 | - | 13.97 | - |
| 抗真菌类(%) | - | 26.91 | - | 32.62 | - |
| 免疫抑制类(%) | - | 8.81 | - | 6.57 | - |
| 权益分成收入(%) | - | - | - | 4.81 | - |
| 制剂类(%) | - | 14.81 | - | 12.91 | - |
| 其他类产品(%) | - | 34.31 | - | 25.98 | - |
| 毛利构成(%) | |||||
| 产品销售收入(%) | 95.18 | - | 86.54 | - | 91.85 |
| 技术权益及服务收入(%) | 4.82 | 15.33 | 13.46 | - | 8.15 |
| 技术收入(%) | - | - | - | 2.88 | - |
| 抗病毒类(%) | - | 1.27 | - | 7.90 | - |
| 抗真菌类(%) | - | 37.27 | - | 41.36 | - |
| 免疫抑制类(%) | - | 8.86 | - | 5.86 | - |
| 权益分成收入(%) | - | - | - | 8.21 | - |
| 制剂类(%) | - | 11.34 | - | 14.22 | - |
| 其他类产品(%) | - | 25.94 | - | 19.59 | - |